Sangamo Therapeutics, Inc.

XTRA:GBY Stock Report

Market Cap: €598.5m

Sangamo Therapeutics Management

Management criteria checks 2/4

Sangamo Therapeutics' CEO is Sandy Macrae, appointed in Jun 2016, has a tenure of 6.42 years. total yearly compensation is $4.74M, comprised of 14.5% salary and 85.5% bonuses, including company stock and options. directly owns 0.091% of the company’s shares, worth €542.87K. The average tenure of the management team and the board of directors is 3.2 years and 3 years respectively.

Key information

Sandy Macrae

Chief executive officer

US$4.7m

Total compensation

CEO salary percentage14.5%
CEO tenure6.4yrs
CEO ownership0.09%
Management average tenure3.2yrs
Board average tenure3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Sandy Macrae's remuneration changed compared to Sangamo Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2022n/an/a

-US$178m

Jun 30 2022n/an/a

-US$172m

Mar 31 2022n/an/a

-US$176m

Dec 31 2021US$5mUS$689k

-US$178m

Sep 30 2021n/an/a

-US$181m

Jun 30 2021n/an/a

-US$135m

Mar 31 2021n/an/a

-US$124m

Dec 31 2020US$4mUS$682k

-US$121m

Sep 30 2020n/an/a

-US$76m

Jun 30 2020n/an/a

-US$102m

Mar 31 2020n/an/a

-US$96m

Dec 31 2019US$4mUS$662k

-US$95m

Sep 30 2019n/an/a

-US$118m

Jun 30 2019n/an/a

-US$104m

Mar 31 2019n/an/a

-US$90m

Dec 31 2018US$4mUS$636k

-US$68m

Sep 30 2018n/an/a

-US$63m

Jun 30 2018n/an/a

-US$62m

Mar 31 2018n/an/a

-US$58m

Dec 31 2017US$2mUS$612k

-US$55m

Sep 30 2017n/an/a

-US$51m

Jun 30 2017n/an/a

-US$58m

Mar 31 2017n/an/a

-US$72m

Dec 31 2016US$4mUS$350k

-US$72m

Compensation vs Market: Sandy's total compensation ($USD4.74M) is above average for companies of similar size in the German market ($USD1.11M).

Compensation vs Earnings: Sandy's compensation has increased whilst the company is unprofitable.


CEO

Sandy Macrae (59 yo)

6.4yrs

Tenure

US$4,735,817

Compensation

Dr. Alexander D. Macrae, also known as Sandy, M.B., Ch B, Ph D., MRCP, serves as an Independent Non-Executive Director of 4D pharma plc since August 27, 2019.Dr. Macrae has been the Chief Executive Office...


Leadership Team

NamePositionTenureCompensationOwnership
Alexander Macrae
CEO, President & Director6.4yrsUS$4.74m0.091%
$ 542.9k
Prathyusha Duraibabu
Senior VP3.4yrsUS$1.06m0.015%
$ 91.1k
D. McClung
Executive VP & COOless than a yearUS$1.66m0.034%
$ 206.1k
R. Ramelmeier
Executive Vice President of Technical Operations3.2yrsUS$1.69m0.026%
$ 158.6k
Jason Fontenot
Senior VP & Chief Scientific Officer1.8yrsno data0.023%
$ 138.2k
Aron Feingold
Head of Corporate Communications & Investor Relations Officerno datano datano data
Scott Willoughby
Senior VP1.3yrsno data0.016%
$ 96.1k
Whitney Jones
Senior VP & Chief People Officer2.8yrsno datano data
Nathalie Dubois-Stringfellow
Senior Vice President of Product Development & Management3.8yrsno data0.015%
$ 90.8k
Heather Erickson
Chief of Staff6.3yrsno datano data
Bettina Cockroft
Senior VP & Chief Medical Officer3.2yrsno datano data
Jaspreet Gill
Senior VP & Chief Quality Officer2.3yrsno datano data

3.2yrs

Average Tenure

55yo

Average Age

Experienced Management: GBY's management team is considered experienced (3.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Alexander Macrae
CEO, President & Director6.4yrsUS$4.74m0.091%
$ 542.9k
H. Parker
Independent Chairwoman of the Board8.4yrsUS$298.06k0.022%
$ 132.2k
Robert Carey
Independent Director6.4yrsUS$273.06k0.014%
$ 84.7k
Stuart Schreiber
Member of Scientific Advisory Board3yrsno datano data
Robert Desnick
Member of Scientific Advisory Board3yrsno datano data
Roger Kornberg
Member of Scientific Advisory Board3yrsno datano data
Samuel A. J. Aparicio
Member of Scientific Advisory Board3yrsno datano data
Jef Boeke
Member of Scientific Advisory Board3yrsno datano data
Karen Smith
Independent Director4.4yrsUS$264.94k0.016%
$ 93.8k
Megan Levings
Member of Scientific Advisory Board3yrsno datano data
Michael Grunstein
Member of Scientific Advisory Board3yrsno datano data
Douglas Higgs
Member of Scientific Advisory Board3yrsno datano data

3.0yrs

Average Tenure

64.5yo

Average Age

Experienced Board: GBY's board of directors are considered experienced (3 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.